Get the Stockscreener App
22.24
4.55%
-1.06
After Hours:
22.24
Kailera Therapeutics Inc stock is traded at $22.24, with a volume of 1.59M.
It is down -4.55% in the last 24 hours and up +14.82% over the past month.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
See More
Previous Close:
$23.30
Open:
$23.3
24h Volume:
1.59M
Relative Volume:
2.31
Market Cap:
$2.88B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.95%
1M Performance:
+14.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$19.90
$23.82
1-Week Range:
$19.90
$23.82
52-Week Range:
$18.50
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Name
Kailera Therapeutics Inc
Sector
Industry
Phone
508-440-9475
Address
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
22.24 | 3.02B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-26 | Initiated | Evercore ISI | Outperform |
| May-12-26 | Initiated | JP Morgan | Overweight |
| May-12-26 | Initiated | Jefferies | Buy |
| May-12-26 | Initiated | Leerink Partners | Outperform |
| May-12-26 | Initiated | TD Cowen | Buy |
| May-12-26 | Initiated | William Blair | Outperform |
View All
Kailera Therapeutics Inc Stock (KLRA) Latest News
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
Kailera falls after late-stage trial data for oral GLP-1 candidate - Seeking Alpha
Kailera shares tumble on high nausea rates despite weight-loss drug's success - Reuters
Kailera reports 11.1% weight loss data - grafa.com
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s obesity drug meets main goal of late-stage trials in China - 101 WIXX
Kailera says obesity pill succeeds in late-stage trial in China - Yahoo Finance
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera’s GLP-1 drug meets main goal of late-stage trials - WTVB
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - Moomoo
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 3000E Value Benchmark - marketscreener.com
Kailera Therapeutics, Inc. (KLRA) Total Assets (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Margin (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (TTM) - Zacks Investment Research
Enterprise value to revenue forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Return On Assets (TTM) - Zacks Investment Research
Price to sales forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Price Book Value - Zacks Investment Research
Price to book forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Price to earnings forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P TMI Index - marketscreener.com
Latest KLRA ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
KLRA Technical Analysis & ETF Price Forecast - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Kardigan surges in Nasdaq debut after upsized $400 million IPO - marketscreener.com
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Kailera Therapeutics, Inc. Common Stock (NASDAQ: KLRA) Stock Price, News & Analysis - Kalkine
This Stock Is Up 58% This Year. Is It too Late to Buy? - AOL.com
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic? - Yahoo! Finance Canada
Parabilis sets biotech IPO record with $670M raise - MSN
Parabilis Is Now the Largest VC-Backed Biotech IPO - Morningstar
Kailera (KLRA) CEO exercises stock options, now holds 38,094 shares - Stock Titan
Parabilis now the largest VC-backed biotech IPO - Yahoo Finance
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record - Citeline News & Insights
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Parabilis takes top spot, pricing largest biopharma IPO at $670M - BioWorld News
Parabilis Medicines raises $670M in upsized IPO - Axios
Kailera Therapeutics Inc Stock (KLRA) Financials Data
There is no financial data for Kailera Therapeutics Inc (KLRA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kailera Therapeutics Inc Stock (KLRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):